FDA panel advises against omeprazole as over the counter drugBMJ 2000; 321 doi: https://doi.org/10.1136/bmj.321.7269.1099/a (Published 04 November 2000) Cite this as: BMJ 2000;321:1099
- Scott Gottlieb
- New York
A panel of expert advisers to the US Food and Drug Administration (FDA) concluded that omeprazole, the world's best selling treatment for chronic heartburn (sold under the brand name Losec in the United Kingdom and Prilosec in the United States), should not be allowed to be sold over the counter. Sales of omeprazole in 1999 reached about $5.9bn (£4.2bn).
In its 9 to 3 vote, the advisory committee said that it was unsure whether patients would take the …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial